The global pyrimethamine market is estimated to be valued at US$ 1,106.8 million in 2022 and expected to increase to US$ 1,655.1 Mn by 2030, witnessing a CAGR of 5.2% over the forecast period (2022-2030).
The rising prevalence of toxoplasmosis infection is expected to drive the growth of the global pyrimethamine market.
Toxoplasmosis is an infection caused by a single-celled parasite called Toxoplasma gondii. The rising prevalence of toxoplasmosis infection is expected to drive the growth of the global pyrimethamine market. As per the sources of the Centers for Disease Control and Prevention (CDC) 2018, in the U.S., an estimated 11% of the 6-year-old population was infected with Toxoplasma gondii. In different places around the world, it is estimated that over 60% of people have been infected with Toxoplasma gondii. The infection rate is generally higher in areas with high heat, humidity, and lower altitudes, as oocysts survive better in these types of environments.
Global Pyrimethamine Market – Impact of Coronavirus (COVID-19) Pandemic
Pyrimethamine Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients